RecruitingNCT07199335
Long-acting cabotegravir for HIV prevention in people who inject drugs
About this title
Read the official source — NCT07199335Medication studyAges 18+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Boston and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 24, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07199335
- Official title
Show the full official title
A Multi-Center Assessment of an Intervention to Provide Long-Acting Cabotegravir Injectable Pre-Exposure Prophylaxis to People Who Inject Drugs
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including APRETUDE (cabotegravir).
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
